Case Study: RDDC RNA Splicer Accurately Predicts Pathogenic Mechanism of ABCA4 Splicing Variant
In the research of inherited retinal diseases, accurately assessing newly discovered variants, especially splice site variants, is crucial for uncovering pathogenic mechanisms and guiding diagnosis. A study involving a patient with Stargardt Disease highlights the key role of the RDDC RNA Splicer Tool (SpliceTool) in this process. In this study, RDDC provided a precise prediction for a newly discovered splice site mutation in the ABCA4 gene, which was highly consistent with subsequent experimental validation results, successfully elucidating the variant's pathogenic mechanism.
Research Challenge: Determining Function of a Newly Discovered Splice Site VUS
The study involved a patient diagnosed with Stargardt disease, exhibiting typical macular atrophy and vision decline symptoms. Whole Exome Sequencing (WES) identified a newly discovered heterozygous mutation in intron 38 of the ABCA4 gene in this patient: c.5461-10T>C.
This variant was absent from public databases, classifying it as a "Variant of Uncertain Significance" (VUS). Determining whether it was the cause of the patient's disease required clarifying its specific impact on ABCA4 mRNA splicing.
RDDC's Precise Prediction: Unveiling Aberrant Splicing Patterns
To assess the functional consequences of this VUS before investing in experimental resources, the research team utilized RDDC's RNA Splicer Tool (SpliceTool) among other bioinformatics tools. RDDC's analysis provided critical, testable hypotheses regarding the pathogenic mechanism, predicting that the c.5461-10T>C variant would lead to aberrant splicing events:
Aberrant Splicing Patterns
Retention of intron 38 sequence: RDDC predicted that the variant would cause partial retention of the intronic sequence in the mature mRNA, resulting in aberrant splicing products.
RDDC's prediction clearly indicated that this aberrant splicing pattern would result in a frameshift and premature protein termination. This would lead to a truncated, non-functional ABCA4 protein, impairing its transport function in retinal pigment epithelial cells.
Clinical Significance: RDDC Prediction Guides Diagnosis and Counseling
The study mentions that RDDC's prediction was highly consistent with subsequent experimental validation results. This strongly confirmed the pathogenicity of the newly discovered c.5461-10T>C splicing mutation. This case demonstrates the powerful capability of RDDC RNA Splicer in functionally analyzing splice site VUS.
Research Value
By providing precise molecular mechanism predictions, RDDC not only helped researchers confirm the pathogenic variant but also offered crucial scientific support for early genetic diagnosis, carrier screening, and genetic counseling for this disease, showcasing the value of the "bioinformatics prediction followed by experimental validation" pathway in rare disease research.
Content Source and Disclaimer
This article is a compilation and interpretation of the scientific study cited below, intended to highlight the application of RDDC bioinformatics tools. All research data and conclusions belong to the original authors and publication.
Original Article
Bauwens M, Garanto A, Sangermano R, et al. ABCA4-associated Stargardt disease: The spectrum of pathogenic sequence variants and their phenotypic consequences. Human Mutation. 2019 Dec;40(12):2195-2223.
Article Link: https://pubmed.ncbi.nlm.nih.gov/31436849/
